ERBB2 and breast cancer: E-cadherin-expressing HER2-overexpressing BC cells were induced to treatment resistance toward trastuzumab, because ADCC activity was inhibited by interaction with E-cadherin and KLRG1 (Yamauchi et al., 2011).